- 2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million
- 2seventy bio to Participate in Upcoming Investor Conferences
- 2seventy bio Reports First Quarter Financial Results and Recent Operational Progress
- 2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024
Key statistics
On Friday, 2Seventy Bio Inc (TSVT:NSQ) closed at 4.03, 162.54% above the 52 week low of 1.54 set on Nov 22, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.96 |
---|---|
High | 4.05 |
Low | 3.88 |
Bid | 3.80 |
Offer | 4.20 |
Previous close | 4.01 |
Average volume | 592.20k |
---|---|
Shares outstanding | 51.41m |
Free float | 50.24m |
P/E (TTM) | -- |
Market cap | 206.14m USD |
EPS (TTM) | -4.34 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 21:00 BST.
More ▼